Future therapy of diabetes mellitus

Biomedicine and Pharmacotherapy

Volumn 58, Issue 10, 2004, Pages 578-581

  Takei, Izumi ^a   Kasatani, Tomohiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dipeptidyl peptidase IV (DPP IV); Glucagon like peptide 1 (GLP 1); Inhaled insulin; Oral insulin delivery; Protein kinase C (PKC)

Indexed keywords

CALCIUM; CJC 1131; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; HEXYL INSULIN MONOCONJUGATE 2; INSULIN; LIRAGLUTIDE; LY 315902; PYRIDOXAMINE; RUBOXISTAURIN; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; ZP 10A;

AMINO ACID SUBSTITUTION; BLOOD GLUCOSE MONITORING; CALCIUM TRANSPORT; DIABETIC NEPHROPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; GLYCOGEN SYNTHESIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SYNTHESIS; KIDNEY CLEARANCE; METERED DOSE INHALER; NAUSEA AND VOMITING; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPATHETIC NERVE; VAGUS NERVE;

EID: 13844315157     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2004.09.008     Document Type: Article

References (28)

1. Y. Anini, and P.L. Brubaker Muscarinic receptors control glucagons-like peptide 1 secretion by human endocrine L cells Endocrinology 144 7 2003 3244 3250
2. D.A. D'Alessio, S.E. Kahn, C.R. Leusner, and J.W. Ensinck Glucagon-like peptide 1 enhances tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal J. Clin. Invest. 93 1994 2263 2266
3. A. Flint, A. Raben, A.K. Ersboll, J.J. Holst, and A. Astrup The effect of physiological levels of glucagons-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity Int. J. Obes. Relat. Metab. Disord 25 2001 781 792
4. H. Hongxiang, N. Arash, Z. Xiaoning, and P. Riccardo Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway Endocrinology 144 4 2003 1444 1455
5. G.H. George, and G.C. Oleg Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus Curr. Med. Chem. 10 2003 2471 2483
6. J. Larsen, B. Hylleberg, K. Ng, and P. Damsbo Glucagon-like peptide-1 infusion must be maintained for 24:h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulfonylurea treatment Diabetes Care 24 2001 1416 1421
7. Buckley DI, Lundquist P. Analysis of the degradation of insulinotropin [GLP-1(7-37)] in human plasma and production of degradation resistant analogs. Regul. Pept.1992; 40:117 [Abstract].
8. K. Adelhorst, B. Hedegaard, L.B. Knudsen, and O. Kirk J. Biol. Chem. 269 1994 6275 6278
9. B. Rolin, M.O. Larsen, C.F. Gotfredsen, C.F. Deacon, and R.D. Carr Am. J. Physiol. Endocrinol. Metab. 283 2002 E745 E752
10. C.B. Juhl, M. Hollingdal, J. Sturis, G. Jakobsen, H. Agerso, and J. Veldhuis Diabetes 51 2002 424 429
11. Bridon DP, Thibaudeau K, Larcheveque BP, Pham K, Robitaille MF, Drucker DJ, et al. 62nd ADA Scientific Sessions, San Francisco, CA 2002:1398-P [Abstract].
12. J.A. Pospisilik, S.G. Stafford, H.U. Demuth, R. Brownsey, W. Parkhouse, and D.T. Finegood Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats Diabetes 51 2002 943 950
13. B. Ahren, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, and P.A. Jansson Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes Diabetes Care 25 2002 869 875
14. D.R. Owens, B. Zinman, and G. Bollit Alternative routes of insulin delivery Diabet Med. 20 2003 886 898
15. P. Modi, M. Mihic, and A. Lewin The evolving role of oral insulin in the treatment of diabetes using a novel RapidMistTM System Diabetes Metab. Res. Rev. 18 Suppl 1 2002 s38 s42
16. D. Lelej-Bennis, J. Boillot, C. Bardin, P. Zirinis, A. Coste, and E. Escudier Six month administration of gelified intranasal insulin in type 1 diabetic patients under multiple injections: efficacy versus subcutaneous injections and local tolerance Diabetes Metab. 27 2001 372 377
17. T. Heise, K. Rave, S. Bott, S. Sha, S.A. Willavize, and S. Gruber Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin Diabetes 39 Suppl 2000 A10
18. S.J. Farr, A. McElduff, L.E. Mather, J. Okikawa, M.E. Ward, and I. Gonda Pulmonary insulin administration using the AERxTM system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects Diabetes Technol. Ther. 2 2000 185 197
19. J.S. Skyler, W.T. Cefalu, I.A. Kourides, W.H. Landshulz, C.C. Balagtas, S.L. Cheng for The Inhaled Insulin Phase II Study Group Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study Lancet 357 2001 331 335
20. K. Hermansen, T. Ronnemaa, A.H. Petersen, and U. Adamson Intensive treatment with pulmonary insulin using the AERx insulin diabetes management system. A proof of concept trial in type 2 diabetic patients Diabetes Suppl 2 2002 A48
21. S. Clement, G. Still, G. Kosutic, and R.G. McAllister Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2 Diabetes Technol Ther 4 2002 459 466
22. M. Kipnes, P. Dandona, and D. Tripathy Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes Diabetes Care 26 2003 421 466
23. S. Clement, P. Dandona, G. Still, and G. Kosutic Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial Metabolism 53 2004 54 58
24. T. Inoguchi Proc. Natl. Acad. Sci. USA 89 1992 11059
25. H. Ishii, M.R. Jirousek, D. Koya, C. Takagi, P. Xia, and A. Clermont Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor Science 272 1996 728 773
26. W. Litchy, P. Dyck, S. Tesfaye, D. Zhang, E. Bastyr The MBBQ Study Group. Diabetic peripheral neuropathy (DPN) assessed by neurological examination (NE) and composite scores (CS) is improved with LY333531 treatment Diabetes 51 Suppl 2 2002 A197
27. N. Cameron, M. Cotter, N. Alderson, S. Thorpe, and J. Baynes Pyridoxamine treatment improves nerve function in diabetic rats Diabetes 52 Suppl 1 2003 A192
28. M. Cotter, and N. Cameron Effects of nuclear factor kappa B inhibition on neurovascular dysfunction in diabetic rats Diabetes 52 Suppl 1 2003 A192